miR-29a expression negatively correlates with Bcl-2 levels in colorectal cancer and is correlated with better prognosis

This publication has 64 references indexed in Scilit:

• MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer
  Clinical and Translational Oncology, 2022
• MicroRNA miR-29a Inhibits Colon Cancer Progression by Downregulating B7-H3 Expression: Potential Molecular Targets for Colon Cancer Therapy
  Molecular Biotechnology, 2021
• MicroRNA: A signature for cancer progression
  Biomedicine & Pharmacotherapy, 2021
• microRNAs: New-Age Panacea in Cancer Therapeutics
  Indian Journal of Surgical Oncology, 2020
• BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
  Apoptosis, 2020
• Familial Risk and Heritability of Colorectal Cancer in the Nordic Twin Study of Cancer
  Clinical Gastroenterology and Hepatology, 2017
• Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer
  Tumor Biology, 2014
• Meta-analyses of colorectal cancer risk factors
  Cancer Causes & Control, 2013
• Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis
  Cancer Epidemiology, 2012
• MicroRNA‐125b suppresses the development of bladder cancer by targeting E2F3
  International Journal of Cancer, 2011